FDA Approves Pluvicto for PSMA+ Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)

RegulatoryapprovedPluvictoPositive

AI Analysis

Summary

Novartis announced FDA approval of Pluvicto (lutetium Lu 177 vipivotide tetraxetan) in combination with ARPI for patients with PSMA+ metastatic hormone-sensitive prostate cancer. This represents a significant regulatory milestone for the company's precision oncology portfolio.

Outcome Details

FDA approval for Pluvicto in combination with androgen receptor pathway inhibitor (ARPI) for mHSPC patients

Importance:9/10

Sentiment:

0.95

FDA approvaloncologyprostate cancerradiopharmaceuticalPSMA-targeted therapy

Related Companies

$NVS

Read the original article

Published by Drugs.com New Drug Approvals on July 31, 2026 8:07 PM

Read Original